The assessment of ALDH1 activity has been considered to be a reliable marker of CSC in malignant neoplasms of the head and neck [44], lung [45], pancreas [46], cervix [47], breast [48], prostate [49], bladder [50] and large intestine [51]. The gene discussed is ALDH1A1; the disease is cancer.